Musculo-skeletal phenotype of Costello syndrome and cardio-facio-cutaneous syndrome: insights on the functional assessment status

Chiara Leoni (chiara.leoni@policlinicogemelli.it)
Fondazione Policlinico Universitario A. Gemelli, IRCCS

Domenico M Romeo
Policlinico Universitario Agostino Gemelli

Pelliccioni Michele
Policlinico Universitario Agostino Gemelli

Di Già Mariangela
Policlinico Universitario Agostino Gemelli

Onesimo Roberta
Policlinico Universitario Agostino Gemelli

Giorgio Valentina
Policlinico Universitario Agostino Gemelli

Flex Elisabetta
Istituto Superiore Di Sanita

Marta Tedesco
Policlinico A Gemelli: Policlinico Universitario Agostino Gemelli

Marco Tartaglia
Ospedale Pediatrico Bambino Gesu

Donato Rigante
Policlinico Universitario Agostino Gemelli

Antonio Valassina
Policlinico Universitario Agostino Gemelli

Giuseppe Zampino
Policlinico Universitario Agostino Gemelli

Research

Keywords: Costello syndrome, cardio-facio-cutaneous syndrome, RASopathies, musculo-skeletal profiling, functional and disability assessment, genotype-phenotype correlation, patient-centered care, innovative biotechnologies, clinical biomarker, personalized medicine, tailored treatments
Abstract

Background

Costello syndrome (CS) and cardio-facio-cutaneous syndrome (CFCS) belong to the RASopathies, a group of neurodevelopmental disorders with skeletal anomalies. Due to their rarity, the characterization of the musculo-skeletal phenotype in both disorders has been poorly characterized.

Patients and methods

Herein we reported data on orthopedic findings and functional status of a large sample of CS and CFCS patients. Thirty-four patients (CS=17 and CFCS=17) were recruited. Functional and disability evaluations were performed by assessing the 6-minute walking test (6MWT) and Pediatric Outcomes Data Collection Instrument (PODCI). Genotype/phenotype correlations was also provided.

Results

Orthopedic manifestations are highly prevalent in CS and CFCS, and do overlap in the two disorders. Overall, patients with CS harboring the recurrent HRAS Gly12Ser substitution show a more severe skeletal phenotype compared to patients carrying the Gly12Ala and Gly13Cys variants. Among CFCS patients, those with MAP2K1/2 pathogenic variant show different skeletal characteristics compared to BRAF variants, with a higher prevalence of orthopedic abnormalities. Functional assessment demonstrates that patients with CS and CFCS reach lower values compared to the general population with CFCS patients showing the lowest scores.

Conclusions

Orthopedic manifestations appear universal features of CS and CFCS and they can evolve along patients’ life. Longitudinal assessment of disability status by using 6MWT and PODCI could be useful to evaluate the functional impact of orthopedic manifestations on patients’ outcome, and help planning a tailored treatment of these comorbidities.

Background

Costello syndrome (CS, OMIM #218040) and cardio-facio-cutaneous syndrome (CFCS, OMIM PS115150) are neurodevelopmental disorders caused by gain-of-function mutations in genes encoding components of the RAS/mitogen-activated protein kinase (MAPK) pathway, an intracellular signaling cascade playing a pivotal role in cell cycle regulation, differentiation, growth and senescence [1]. These conditions are grouped under the term RASopathies together with Noonan syndrome (NS) and neurofibromatosis type 1 (NF1) and other emerging clinically related disorders, due to a common pathogenetic mechanism resulting in dysregulation of the RAS/MAPK pathway [2]. Both CS and CFCS are ultra-rare conditions with approximately 300 individuals each reported worldwide [3-4]. CS is caused by heterozygous activating mutations in the HRAS gene, with a missense change resulting in the Gly12Ser substitution representing
the most common event underlying the disorder. As a consequence, CS is characterized by a relatively homogeneous phenotype [3]. Conversely, CFCS is genetically heterogeneous, and caused by heterozygous activating mutations in the \textit{BRAF}, \textit{MAP2K1}, \textit{MAP2K2} and \textit{KRAS} genes, leading to a more variable clinical presentation [4]. Overall, key features affecting RASopathies include a distinctive facial appearance, postnatal growth failure, a wide spectrum of cardiac defects, variable intellectual disability, skin manifestations and different signs of musculo-skeletal involvement. The musculo-skeletal profiling of NS and NF1 syndrome has previously been outlined in the medical literature [5-7], while incidence similar characterization is lacking for both CS and CFCS, possibly because their overall lower prevalence. Indeed, available data on skeletal anomalies in CS and CFCS have been collected during the International Costello Syndrome Conferences [8-14] and poor information is available about the function and disability level [8,16] or daily living activities in these patients [17].

The present study aimed to improve our general knowledge about the musculo-skeletal phenotype of CS and CFCS thorough the assessment of a single, unselected and relatively large monocentric cohort of patients, and to add information about the functional status of such patients. Moreover, we present first genotype/phenotype correlations.

\textbf{Patients And Methods}

A prospective study was performed between May 2018 and January 2020. Patients with molecularly confirmed diagnosis of CS and CFCS followed in our Institution, were consecutively recruited. A written informed consent was obtained from all participating individuals and families. The study was approved by the local Ethics Committee. All individuals underwent pediatric, genetic, neurological and orthopedic evaluations by physicians experienced in the management of RASopathies. Patients’ past medical history was reviewed in order to check for: i) congenital orthopedic malformations; ii) achievement of neuro-motor developmental milestones; iii) use of orthosis; iv) physical activity.

A standardized musculo-skeletal physical examination was carried out by filling in a comprehensive checklist, including 100 items assessment (\textbf{Table 1 supplementary data}). Coxa valga subluxans (CVS) was radiologically diagnosed when femoral neck-shaft angle was >140°. Functional and disability evaluations were performed by assessing the 6-minute walking test (6MWT) [18] in all patients with independent walking and by using the Pediatric Outcomes Data Collection Instrument (PODCI) [16,19-20]. The 6MWT was used to measure the distance covered on a flat and hard surface in a total of six minutes, to monitor overtime worsening of general status and deambulation [18]. 6MWT data were normalized taking into account sex, age, body mass index and height [21-22]. PODCI was used to assess the global (functional and psychological) profile of the orthopedic patient. Based on the global level of intellectual disability, PODCI was filled in by patients’ parents or caregivers; data on all PODCI domains (physical functions, transfer and basic mobility, sports, comfort, pain, happiness and satisfaction, global function) were collected.
Study data were analyzed with GraphPad PRISM software (version 5.1; GraphPad Software. Inc., San Diego CA, USA). Descriptive analysis was expressed as mean ± standard deviation (SD) and percentages. According to the cut-off age identified by PODCI, the whole sample was divided into two groups: children (when <11 years), adolescents and young adults (if ≥11 years).

The nonparametric Mann Whitney test was used to compare orthopedic findings in CS and CFCS, PODCI scores between CS and CFCS and with normative values [20]. A p value <0.05 was considered statistically significant.

Results

A total of 34 patients with molecularly confirmed diagnosis of CS (N=17) and CFCS (N=17) were recruited in the study (CS: age range 4-36 years; CFCS: age range 5-35 years); most of patients were older than 8 years (15/17 with CS and 12/17 with CFCS) (Table 1). No one patient reported in the present paper was ever enrolled in previous studies about orthopedic anomalies in CS and CFCS. Prevalence of congenital malformations detected at birth was very low (hip dysplasia 3/34, 9%; clubfoot 2/34, 6%) (Table 2).

All patients experienced a delay in the neuromotor development milestones, which was treated with dedicated physical therapy, requiring the use of orthosis (mostly insoles, orthopedic shoes and ankle foot orthosis or AFO) in 15 (88%) CS patients and 13 (76%) CFCS patients (Table 2). At the time of clinical evaluation, all patients with CS reached head and trunk control, and 16/17 achieved an independent walking. In contrast, 6 (35%) patients with CFCS needed some kind of support for standing an upright position and/or deambulation (orthosis and/or wheelchair for long distances). Most of patients played sport and/or performed physical therapy at the time of clinical evaluation (14/17, 82% CS; 13/17, 76% CFCS) (Table 2). The standardized checklist to detect musculo-skeletal manifestations revealed that most patients were affected by a variable combination of deformities; the most frequent osteo-articular abnormalities are shown in Table 3. The most frequent skeletal findings in CS were scoliosis, anterior chest anomalies, ulnar deviation of fingers, elbows contractures, cubitus valgus, feet anomalies (metatarsus varus, pes planus or cavus), Achille's tight heel cord and small joint laxity. Overall, patients with CS harboring the Gly12Ser variant showed a more severe skeletal phenotype compared to patients carrying other HRAS pathogenic variant (e.g., Gly12Ala and Gly13Cys). Scoliosis in CFCS was more prevalent compared to CS; other frequent skeletal findings were pectus anomalies and pterigium colli. Ulnar deviation of fingers, elbows contractures and cubitus valgus were also present, but they were less prevalent than in CS. Hip and knees contractures and feet anomalies (mostly characterized by pes valgus and planus) were also frequent. In the CFCS group, patients with MAP2K1/2 pathogenic variant showed different skeletal characteristics compared to those carrying BRAF variants, with a higher prevalence of scoliosis, pectus anomalies, upper limbs anomalies, hip contractures and pes valgus compared to BRAF pathogenic variant. Statistical analysis to compare orthopedic findings detected in CS vs CFCS (full cohorts) did not reach significance for any item. At the time of clinical evaluation, coxa valga subluxans was radiologically documented in 7/8 patients with CS (88%) and 3/11 patients with CFCS and BRAF pathogenic variant (27%). However, one patient with CS (Gly12Ser) was radiologically negative for hip subluxation at the time of recruitment, though she was surgically treated at the age of 5 years for this
problem. Generalized muscular hypotrophy (small and flabby muscles both in upper and lower limbs) was detected in most of patients with CS and CFCS, with a higher prevalence in CS (Table 3).

Functional and disability evaluations were performed by using the 6MWT and PODCI scale, respectively. A total of 24 patients were able to perform the 6MWT (12/17 CS and 12/17 with CFCS). Among the 5 patients with CS who did not perform the test, 1/17 did not reached independent walking at the time of clinical evaluation, 2/17 had undergone surgical interventions and they were in the post-operative period, and 2/17 patients complained of hip pain due to hip dislocation. In the CFCS subcohort, the 5 patients who were not able to perform the 6MWT showed multiple musculo-skeletal deformities associated with loss of walking ability and severe epilepsy. Overall, the CS and CFCS groups covered on average 49% and 46% of the expected distance, respectively. No significant differences occurred between genetic analysis, phenotypes, gender or age of assessment (Figure 1). The average PODCI scores for CFCS (both children and adolescents/young adults) were constantly lower compared to CS population (Figure 2 and 3). Statistically significant differences between CFCS and CS patients were recorded in the following domains: upper-extremities mobility (children $p=0.04$, adolescents and young adults $p=0.01$), transfer and basic mobility (children $p=0.04$, adolescents and young adults $p=0.03$) and global functioning domains (adolescents and young adults $p=0.02$). When compared to normative values, the CFCS group (both children and adolescents/young adults’ sub-groups) reached significantly lower scores in all domains, with the exception of comfort and pain in the group of children ($p=0.2$). Significant differences between CS and normative values were detected in all domains, with the exception of happiness both in children ($p=0.3$) and adolescents/young adults ($p=0.08$) (Fig 3). The prevalence of main orthopedic findings and the comparison with literature data are shown in the Table 4.

**Discussion**

In the present study, the musculo-skeletal phenotype and functional status of CS and CFCS were assessed considering a single unselected and relatively large monocentric cohort of patients, and genotype/phenotype correlations were explored. We report that orthopedic manifestations are highly prevalent in both disorders. Compared with previously published observations, the different prevalence of these features could be related to the different ages of patients recruited in the cohorts [8-13]. As demonstrated by the need of orthosis and surgical intervention, the musculo-skeletal phenotype of CS and CFCS evolves with age; for this reason the routinely use of functional tests could help physicians to plan a timely treatment before worsening of autonomy skills.

According to the medical literature, in CS approximately 80% of mutations result in a Gly12Ser missense change, which is associated with the classic CS phenotype [14]. Based on current evidence and on our analyses, we speculate that CS patients carrying the Gly12Ser variant show a higher prevalence of orthopedic abnormalities compared to subjects with other pathogenic variants in HRAS. The Gly13Cys mutation shows a milder orthopedic phenotype. This add further information about this purely represented cohort of patients with CS; moreover, it is in line with previous observations demonstrating a milder neurodevelopmental impairment, a better growth outcome and a lower risk for malignant tumors.
compared to the classical Gly12Ser variant [14,15]. On the same way, our study documents that patients with CFCS harboring the MAP2K1/2 pathogenic variants generally show a more severe skeletal phenotype compared to other CFCS patients, with a higher prevalence of scoliosis and multiple joint contractures.

Limitations of this study were certainly the small sample of patients with uncommon pathogenic variants and different ages of subjects recruited, even though most patients were older than 8 years. In order to confirm these data, we recommend future multicentric studies, including larger cohorts of patients with less frequent variants of HRAS and MAP2K1/2 genes.

The prevalence of congenital bone deformities detected in our sample was low; although the high prevalence of coxa valga subluxans in our CS population suggests that orthopedic phenotype may evolve in the long-term, highlighting the importance to perform a hip X-ray since infancy to rule out this possible finding. In our sample, some deformities, such as pes planus and tight Achille's heel cord, were surgically treated during patients' life and therefore some specific items could be underestimated.

Both CFCS and CS patients frequently required use of orthosis and postural/mobility devices to improve posture and facilitate acquisition of neurodevelopmental milestones. In particular, CFCS patients reported a higher need of stroller and corset, as they had a higher incidence of scoliosis and lower limb contractures (especially knee and hip contractures), as already reported in the medical literature [11]. In our cohort, these deformities showed a progressive and worsening pattern, needing surgical intervention in some cases and compromising the independent walking.

Generalized muscular hypotrophy and hypotonia were detected in most patients. Skeletal muscle hypotonia of varying degree is a universal finding in CS and CFCS, and some authors speculated that this could be related to myopathy [23]. Tidyman et al., reported muscle biopsies in a limited number of CS and CFCS patients, describing the presence of abnormal muscle fiber size and variability as one of the potential mechanisms leading to hypotonia. Due to the small number of biopsies available, the same authors concluded that since overall muscle tissue's architecture was relatively intact, experiments on animal models would be essential to better define this myopathy in vivo [23]. As it has been demonstrated the vital role of the RAS/MAPK pathway in the myogenesis regulation, mainly in myoblast differentiation and proliferation [23-24], we speculate that decreased muscle fiber size and hypotonia in CS and CFCS could result from inhibition of myoblast differentiation during early muscle development, and this could explain both muscle hypotrophy found in our patients and their functional status.

As expected, CS and CFCS patients showed a worse functional performance and level of disability assessed by both 6MWT and PODCI scales, compared to normative values. All patients able to walk performed 6MWT, covering less than 50% of the expected distance. Overall, the walked distance decreased proportionally to the patient's age and, in particular, patients with CFCS showed worse performances compared to CS. This finding has been also confirmed by the PODCI scale. Global functioning items between children with CS and CFCS was not significantly different, and we speculate that this could be related to the high level of global care assistance needed by children with these genetic
conditions. The lower PODCI scale scores collected in CS and CFCS compared to normative data suggest how cognitive impairment, complex clinical history, neurological condition and musculo-skeletal deformities have a great impact on the disability in RASopathies. Data on functional and disability status published by Johnson et al. detected lower scores in CS compared to CFCS [16]. Interestingly, both Johnson's and our study did not detect a significant difference in the comfort and pain domains between syndromic patients and normative values. We believe that parents’ report could represent a crucial bias since detection of pain in patients with intellectual disability is quite challenging [25]. On the same way, the absence of significant differences between happiness domain in CS versus normative values could be related to the friendly behavior shown by patients with CS [26].

Overall, the musculo-skeletal manifestations in CS and CFCS should be included in a more comprehensive clinical assessment, in which growth and neurodevelopmental delay have to be considered as universal features. We speculate that worsening of the neurological profile in terms of behavioral pattern and epilepsy in CFCS [27] and the abnormal posture and bone health in CS [28-29] may contribute to adult outcome, justifying the lower PODCI scores found in our patients compared to normatives. Results of the 6MWT and PODCI scales underscore how the routinely assessment of disability status could be useful to evaluate the functional impact of orthopedic and neurological manifestations on patients’ outcome to monitoring their worsening and planning a tailored treatment of comorbidities.

The adequate classification of musculo-skeletal deformities and their overtime monitoring together with disability status assessment could represent issues to assess in the frame of future clinical trials.

Conclusions

Previous studies focused on prevalence of musculo-skeletal phenotype in CS and CFCS highlighting the wide clinical variability of orthopedic malformations in these syndromes and their frequent overlap. This paper adds further information about the impact that multiple orthopedic abnormalities have on functional status. The routinely use of both 6MWT and PODCI scale together with the orthopedic evaluation would be relevant to monitor the progression and the impact of orthopedic malformations on disability along life and to plan a timely treatment (conservative or surgical). Early use of the orthosis is also suggested to reduce the progressive onset and worsening of contractures, especially in the lower limbs, and consequently reduce surgical indications. When necessary, surgical treatment should be performed as early as possible to allow minimally invasive or low impact surgical techniques; in fact, the severe progressive worsening of such deformities may lead to complex orthopedic surgery often unsustainable for these fragile patients. In this view, the precocious classification of musculo-skeletal deformities and their careful monitoring over time is of crucial relevance.

Abbreviations
CS: Costello syndrome; CFCS: cardio-facio-cutaneous syndrome; NS: Noonan syndrome; 6MWT: 6-minute walking test; PODCI: Pediatric Outcomes Data Collection Instrument.

Declarations

Acknowledgments

We would like to thank all patients and their families for consenting to participate in this study. We greatly thank the family support group (Associazione Italiana Sindromi Costello e CFC). We finally thank A. Santoro e M. Malagisi for supporting the medical and paramedical staff.

Authors’ contribution

Dr Leoni conceptualized and designed the study and data collection instruments, interpreted data, wrote the manuscript, revised the manuscript for important intellectual content. Dr Romeo analysed and interpreted data, reviewed results and drafted the article. Drs Pelliccioni, Di Già, Tedesco, Onesimo and Giorgio collected, and interpreted data. Drs Flex and Tartaglia interpreted clinical data and drafted the article. Dr Rigante analysed data and thoroughly reviewed the manuscript for both content and significance. Dr Valassina conceptualized the study and reviewed the manuscript for important intellectual content. Dr Zampino conceptualized the study and critically revised the manuscript.

All authors approved the final version of the manuscript as submitted and they agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work.

Funding

M.T. is funded by the Italian Ministry of Health (Ricerca Corrente 2019 and 2020) and European Joint Program on Rare Diseases (NSEuroNet).

Availability of data and materials

Data available from the corresponding author on request from physicians.

Ethics approval and consent to participate

The study was approved by our Institutional Ethic Committee. Parents’ patients signed a written informed consent.

Conflict of interest

None.

Consent for publication
Not applicable.

References

[1] Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci. 2010; 1214:99-121

[2] Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. 2011; 25:161-79

[3] Gripp KW, Morse LA, Axelrad M, Chatfield KC, Chidekel A, Dobyns W, et al. Costello syndrome: Clinical phenotype, genotype, and management guidelines. Am J Med Genet A. 2019;179:1725-1744

[4] Pierpont ME, Magoulas PL, Adi S, Kavamura MI, Neri G, Noonan J, et al. Cardio-facio cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2014;134:e1149-e1162

[5] Stevenson DA, Yang FC. The musculoskeletal phenotype of the RASopathies. Am J Med Genet C Semin Med Genet. 2011;157:90-103

[6] Rhodes SD, Zhang W, Yang D, Yang H, Chen S, Wu X et al. Dystrophic spinal deformities in a neurofibromatosis type 1 murine model. PLoS One. 2015; 10:e0119093

[7] Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017; 3:17004

[8] Yassir WK, Grottkau BE, Goldberg MJ. Costello syndrome: orthopaedic manifestations and functional health. J Pediatr Orthop. 2003; 23:94–98

[9] White SM, Graham JM, Jr, Kerr B, Gripp K, Weksberg R, Cytrynbaum C et al. The adult phenotype in Costello syndrome. Am J Med Genet A. 2005; 136:128–135

[10] Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med Genet. 2008; 45:249–254
[11] Reinker KA, Stevenson DA e Tsung A. Orthopaedic conditions in Ras/MAPK related disorders. J Pediatr Orthop. 2011; 31:599-605

[12] Stevenson DA, Allen S, Tidyman WE, Carey JC, Viskochil DH, Stevens A et al. Peripheral muscle weakness in RASopathies. Muscle Nerve. 2012; 46:394-9

[13] Detweiler S, Thacker MM, Hopkins E, Conway L, Gripp KW. Orthopedic manifestations and implications for individuals with Costello syndrome. Am J Med Genet Part A. 2013; 161:1940-1949

[14] Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI, Jr, Doyle D et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet Part A. 2006; 140:1-7.

[15] Leoni C, Giorgio V, Onesimo R, Kuczynska E, Zampino G. Impact of Costello syndrome on growth patterns. Am J Med Genet Part A. 2020; doi: 10.1002/ajmg.a.61812

[16] Johnson B, Goldberg-Strassler D, Gripp K, Thacker M, Leoni C, Stevenson D. Function and disability in children with Costello syndrome and Cardiofaciocutaneous syndrome. Am J Med Genet A. 2014; 167:40-4

[17] Axelrad ME, Schwartz DD, Katzenstein JM, Hopkins E, Gripp KW. Neurocognitive, adaptive and behavioral functioning of individuals with Costello syndrome: a review. Am J Med Genet C Semin Med Genet. 2011; 157:115-122

[18] American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166:111–117

[19] Daltroy LH, Liang MH, Fossel AH, Goldberg MJ. The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America. J Pediatr Orthop. 1998; 18:561-71

[20] Haynes RJ and Sullivan E. The Pediatric Orthopaedic Society of North America pediatric
orthopaedic functional health questionnaire: an analysis of normal. J Pediatr Orthop. 2001; 21:619

[21] Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-minute walk test in children and adolescents. J Pediatr. 2007; 150:395-9

[22] Jenkins S, Cecins N, Camarri B, Williams C, Thompson P, Eastwood P. Regression equations to predict 6-minute walk distance in middle-aged and elderly adults. Physiother Theory Pract. 2009; 25:516-22

[23] Tidyman WE, Lee HS e Rauen KA. Skeletal muscle pathology in Costello and Cardio-Facio Cutaneous Syndromes: developmental consequences of germline Ras/MAPK activation on myogenesis. Am J Med Genet Part C. 2011; 157: 104-114

[24] Jo C, Jang BG, Jo SA. MEK1 plays contrary stage-specific roles in skeletalmyogenic differentiation. Cell Signal. 2009; 21:1910-7

[25] Leoni C, Triumbari EKA, Vollono C, Onesimo R, Podagrosi M, Giorgio V, et al. Pain in individuals with RASopathies: Prevalence and clinical characterization in a sample of 80 affected patients. Am J Med Genet A. 2019;179:940-947

[26] Alfieri P, Piccini G, Caciolo C, Perrino F, Gambardella ML, Mallardi M, et al. Behavioral profile in RASopathies. Am J Med Genet A. 2014; 164:934-42

[27] Yoon G, Rosenberg J, Blaser S, Rauen KA. Neurological complications of cardio-facio cutaneous syndrome. Dev Med Child Neurol. 2007; 49:894-9

[28] Dileone M, Zampino G, Proifice P, Pilato F, Leoni C, Ranieri F et al. Dystonia in Costello syndrome. Parkinsonism Relat Disord. 2012;18:798-800

[29] Leoni C, Stevenson DA, Martini L, De Sanctis R, Mascolo G, Pantaleoni F, et al. Decreased bone mineral density in Costello syndrome. Mol Genet Metab. 2014;111:41-45

Tables
Table 1: Demographic and body mass index characteristics of the study population

| Phenotype | Gene variant           | N° of patients | Age   | BMI  | Total |
|-----------|------------------------|----------------|-------|------|-------|
| CS        | **HRAS (p.Gly12Ser)**  | 14 (4 M; 10 F) | 19.8±9.7 | 19.2±3.0 | 17 (6 M; 11 F) |
|           | **HRAS (p.Gly13Cys)**  | 2 (1 M; 1 F)  | 14.5±2.1 | 17.2±0.2 |       |
|           | **HRAS (p.Gly12Ala)**  | 1 (1 M; 0 F)  | 8      |       |       |
| CFCS      | **BRAF (all variants)** | 13 (3 M; 10 F) | 12.7±6.2 | 16.7±2.6 | 17 (6 M; 11 F) |
|           | **MAP2K1 (all variants)** | 3 (2 M; 1 F)  | 23.6±9.0 | 15.0±1.4 |       |
|           | **MAP2K2 (p.Ala62Pro)** | 1 (1 M; 0 F)  | 7      |       | 17.4  |

*BRAF variants: 3/13: p.Gln257Arg; 1/13: p.Val487Gly; 1/13: p.Thr599Ile; 1/13: p.Trp531Arg; 1/13: p.Thr470Pro; 1/13: p.Lys601Gln; 1/13: p.Leu525Pro; 1/13: p.Trp531Cys; 1/13: p.Lys483Asn; 1/13: p.Lys499Asn; 1/13: p.Gln709Arg. **MAP2K1 variants: 2/3: p.Tyr130Cys; 1/3: p.Leu42Phe

Table 2: Relevant medical findings

| CS       | N=17 (%) | CFCS | N=17 (%) |
|-----------|----------|------|----------|
| **Congenital orthopedic malformation** | | | |
| Congenital hip dysplasia | 2 (12) | 1 (6) | |
| Clubfoot | 1 (6)    | 1 (6) | |
| **Neuro-motor abilities** | | | |
| Head control | 17 (100) | 17 (100) | |
| Trunk control | 17 (100) | 16 (94) | |
| Autonomous deambulation | 17 (100) | 11 (65) | |
| Assisted Walking | 0 (0) | 6 (35) | |
| **Past use of orthosis** | | | |
| 15 (88) | 13 (76) | |
| **Use of orthosis** | | | |
| DAFO/AFO | 5 (29) | 4 (24) | |
| Postural Stroller | 1 (6) | 6 (35) | |
| Corset/Belt/Brace | 0 (0) | 3 (18) | |
| Orthopedic Insole | 8 (47) | 8 (47) | |
| **Physical activity** | | | |
| Physical therapy | 4 (24) | 13 (76) | |
| Sport | 10 (58) | 5 (29) | |

*Prevalence data refers to acquired neuro-motor ability at time of clinical evaluation; * Data showed at time of clinical evaluation; # We considered physical therapy or sport played ≥ 2 times per week
Table 3: Muscle-skeletal findings

|                     | CS N=17 (%) | HRAS Gly12Ser (N=14) | HRAS Gly12Ala (N=1) | HRAS Gly13Cys (N=2) | CFCS N=17 (%) | BRAF all variants (N=13) | MAP2K1/2 all variants (N=4) |
|---------------------|-------------|----------------------|---------------------|---------------------|---------------|-------------------------|-----------------------------|
| **Axial**           |             |                      |                     |                     |               |                         |                             |
| Scoliosis           | 5 (29)      | 5 (36)               | 0 (0)               | 0 (0)               | 6 (35)        | 4 (31)                  | 2 (50)                      |
| Pectus Carinatum/excavatum | 8 (47)    | 8 (57)               | 0 (0)               | 0 (0)               | 9 (53)        | 6 (46)                  | 3 (75)                      |
| Dorsal Hyperkyphosis| 3 (18)      | 2 (14)               | 0 (0)               | 1 (50)              | 3 (18)        | 3 (23)                  | 0 (0)                       |
| Stiff Back          | 3 (18)      | 2 (14)               | 0 (0)               | 1 (50)              | 3 (18)        | 3 (23)                  | 0 (0)                       |
| Pterigium colli     | 0 (0)       | 0 (0)                | 0 (0)               | 0 (0)               | 6 (35)        | 5 (38)                  | 1 (25)                      |
| Lumbar hyperlordosis| 1 (6)       | 1 (7)                | 0 (0)               | 0 (0)               | 1 (6)         | 1 (8)                   | 0 (0)                       |
| **Upper limbs**     |             |                      |                     |                     |               |                         |                             |
| Fingers’ ulnar deviation | 14 (82) | 13 (93)              | 1 (100)             | 0 (0)               | 7 (41)        | 3 (23)                  | 4 (100)                     |
| Elbows contractures | 9 (53)      | 8 (57)               | 0 (0)               | 1 (50)              | 6 (35)        | 4 (31)                  | 2 (50)                      |
| Cubitus valgus      | 6 (35)      | 4 (29)               | 0 (0)               | 2 (100)             | 4 (24)        | 3 (23)                  | 1 (25)                      |
| Wrist contractures  | 2 (12)      | 2 (14)               | 0 (0)               | 0 (0)               | 1 (6)         | 0 (0)                   | 1 (25)                      |
| Fingers’ radial deviation | 0 (0) | 0 (0)                | 0 (0)               | 0 (0)               | 1 (6)         | 1 (8)                   | 0 (0)                       |
| **Lower limbs**     |             |                      |                     |                     |               |                         |                             |
| Coxa valga subluxans*| 8 (89)   | 7 (87)               | 1 (100)             | -                   | 3 (27)        | 3 (33)                  | 0 (0)                       |
| Hip contractures    | 2 (12)      | 2 (14)               | 0 (0)               | 0 (0)               | 6 (35)        | 2 (15)                  | 3 (75)                      |
| Adducted hip        | 2 (12)      | 1 (7)                | 0 (0)               | 1 (50)              | 3 (18)        | 1 (8)                   | 2 (50)                      |
| Knees contractures  | 3 (18)      | 3 (21)               | 0 (0)               | 0 (0)               | 6 (35)        | 4 (31)                  | 2 (50)                      |
| Genu valgum         | 5 (29)      | 5 (36)               | 0 (0)               | 0 (0)               | 3 (18)        | 1 (8)                   | 2 (50)                      |
| Genu varum          | 0 (0)       | 0 (0)                | 0 (0)               | 0 (0)               | 2 (12)        | 1 (8)                   | 1 (25)                      |
| Metatarsus varus    | 8 (47)      | 7 (50)               | 0 (0)               | 1 (50)              | 6 (35)        | 4 (31)                  | 2 (50)                      |
| Pes valgus          | 4 (24)      | 4 (29)               | 0 (0)               | 0 (0)               | 9 (53)        | 6 (46)                  | 3 (75)                      |
| Pes planus          | 6 (35)      | 5 (36)               | 1 (100)             | 0 (0)               | 6 (35)        | 4 (31)                  | 2 (50)                      |
| Pes cavus           | 6 (35)      | 4 (29)               | 0 (0)               | 2 (100)             | 1 (6)         | 0 (0)                   | 1 (25)                      |
| Hallux valgus       | 4 (24)      | 4 (29)               | 0 (0)               | 0 (0)               | 2 (12)        | 1 (8)                   | 1 (25)                      |
| Condition                        | Count (% of total) | Count (100) | Count (23) | Count (25) |
|---------------------------------|-------------------|-------------|------------|------------|
| **Foot heelcord contractures**  |                   |             |            |            |
| Equinovarus foot                | 0 (0)             | 0 (0)       | 1 (6)      | 1 (8)      | 0 (0)      |
| Supinated foot                  | 0 (0)             | 0 (0)       | 1 (6)      | 1 (8)      | 0 (0)      |
| Clino-/syn-/campto- dactyly     | 6 (35)            | 6 (43)      | 0 (0)      | 4 (23)     | 3 (25)     |
| **Others**                      |                   |             |            |            |
| Small joint laxity              | 7 (41)            | 5 (36)      | 1 (100)    | 5 (29)     | 4 (31)     | 1 (25)     |
| Congenital hip Dislocation      | 2 (12)            | 2 (14)      | 0 (0)      | 1 (6)      | 1 (8)      | 0 (0)      |
| Talipes                         | 1 (6)             | 1 (7)       | 0 (0)      | 1 (6)      | 1 (8)      | 0 (0)      |
| Generalized muscular hipotrophy | 14 (82)           | 12 (86)     | 0 (0)      | 12 (71)    | 8 (62)     | 4 (100)    |

*Coxa valga subluxans diagnosed by X-Rays; §Of note 8/17 patients already performed Achille’s heel cord lengthening at time of clinical evaluation
Table 4: Actual main orthopedic findings and literature data review

|                      | Present data | Reinker et al., 2011 | Detweiler et al., 2013 | White et al., 2005 | Yassir et al., 2003 | Armour et al., 2008 |
|----------------------|--------------|-----------------------|------------------------|--------------------|---------------------|---------------------|
|                      | CS           | CFCS                  | CS                     | CS                 | CS                  | CS                  |
|                      | N=17 (%)     | N=17 (%)              | N=2 (%)                | N=32 (%)           | N=43 (%)           | N=17 (%)‡           |
| Spine                |              |                       |                        |                    |                     |                     |
| Scoliosis            | 5 (29)       | 6 (35)                | 1 (50)                 | 8 (25)             | 25/40 (36)         | 10 (59)             |
|                      |              |                       |                        |                    |                     | 3/18 (17)‡          |
|                      |              |                       |                        |                    |                     | 11/33 (33)          |
| Kyphosis             | 3 (18)       | 3 (18)                | 0 (0)                  | 6 (19)             | 23/40 (58)         | 3 (18)              |
|                      |              |                       |                        |                    |                     | 3/18 (17)‡          |
|                      |              |                       |                        |                    |                     | 6/26 (23)           |
| Lordosis             | 1 (6)        | 1 (6)                 | 0 (0)                  | 1 (3)              | 6/32 (19)          | NA                  |
|                      |              |                       |                        |                    |                     | NA                  |
|                      |              |                       |                        |                    |                     | NA                  |
| Upper extremities    |              |                       |                        |                    |                     |                     |
| Cubitus valgus       | 5 (29)       | 4 (24)                | 1 (50)                 | 0 (0)              | NA                  | NA                  |
|                      |              |                       |                        |                    |                     | NA                  |
| Elbow contracture    | 9 (53)       | 5 (30)                | 1 (50)                 | 4 (12)             | 21/38 (55)         | NA                  |
|                      |              |                       |                        |                    |                     | 10/16 (63)          |
| Ulnar Deviation      | 14 (82)      | 6 (35)                | NA                     | NA                 | 26/41 (63)         | 4/18 (22)           |
|                      |              |                       |                        |                    |                     | NA                  |
| Lower extremities    |              |                       |                        |                    |                     |                     |
| Hip dysplasia        | 8/9 (89)§    | 3 (27)§               | 0 (0)                  | 5 (16)             | 17/38 (45)         | NA                  |
|                      |              |                       |                        |                    |                     | 3/18 (17)‡          |
| Genu valgum          | 5 (29)       | 3 (18)                | NA                     | NA                 | 7/28 (25)          | NA                  |
|                      |              |                       |                        |                    |                     | NA                  |
| Knee contracture     | 3 (18)       | 6 (35)                | 1 (50)                 | 7 (22)             | 13/40 (33)         | NA                  |
|                      |              |                       |                        |                    |                     | NA                  |
| Vertical talus       | 0 (0)        | 0 (0)                 | NA                     | NA                 | 7/41 (17)          | 4 (24)              |
|                      |              |                       |                        |                    |                     | 5/18 (28)           |
| Bilateral talipes    |              |                       |                        |                    |                     |                     |
| equinovarus          | 0 (0)        | 3 (18)                | 0 (0/2)                | 5 (16)             | 1/41 (2)           | 1 (6)               |
|                      |              |                       |                        |                    |                     | NA                  |
| Pes planus           | 6 (35)       | 6 (35)                | 1 (50)                 | 20 (62)            | 19/36 (53)         | NA                  |
|                      |              |                       |                        |                    |                     | 7/16 (44)           |
| Pes cavus            | 6 (35)       | 1 (6)                 | 0 (0)                  | 2 (6)              | 3/40 (8)           | 4/17 (24)           |
|                      |              |                       |                        |                    |                     | NA                  |
| Clino-/Syn-/Campto-  | 6 (35)       | 4 (24)                | 0 (0)                  | 4 (12)             | 11/41 (27)         | NA                  |
| dactyly              |              |                       |                        |                    |                     | 6/16 (38)           |
| Metatarsus varus     | 8 (47)       | 6 (35)                | 0 (0)                  | 2 (6)              | NA                  | NA                  |
|                      |              |                       |                        |                    |                     | NA                  |
| Hallux valgus        | 4 (24)       | 2 (12)                | 0 (0)                  | 2 (6)              | 3/39 (8)           | NA                  |
|                      |              |                       |                        |                    |                     | NA                  |
| Others               |              |                       |                        |                    |                     |                     |
| Pectus excavatum/carinatum | 9 (53)       | 8 (47)                | 0 (0)                  | 4 (12)             | 12/40 (30)         | 8/13 (62)           |
|                      |              |                       |                        |                    |                     | 1/16 (6)            |
| Joint Laxity         | 7 (41)       | 5 (29)                | NA                     | 4 (12)             | 35/41 (85)         | 3/3 (100)           |
|                      |              |                       |                        |                    |                     | 16/16 (100)         |
| Achille tendon       | 8 (47)       | 1 (6)                 | NA                     | 17/43 (40)         | 14/17 (82)         | 8/18 (44)†          |
| release              |              |                       |                        |                    |                     |                     |

* In this population 1/2 patients with CS and 19/32 patients with CFCS, received a molecular confirmation; †Patients without genetic confirmation; ‡coxa valga subluxans based on X-Rays, †5 surgically treated and 3 with serial casting.

Figures
Figure 1

Six minute walk test in CS and CFCS
Figure 2

PODCI scores in Children (population under 11 years of age)

Figure 3

PODCI scores in Adolescents and young adults (population over 11 years of age).